Bronchial asthma on mount kilimanjaro is not a disadvantage

Thorax

Volumn 63, Issue 10, 2008, Pages 936-937

  Stokes, S ^a,b   Kalson, N ^b,c   Earl, M ^b,c   Frost, H ^b,c   Whitehead, A G ^b,c   Tyrrell Marsh, I ^b,d   Davies, A ^b,c  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b MARS Manchester Altitude Research Society

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; STEROID;

ALTITUDE DISEASE; ARTERIAL OXYGEN SATURATION; ASTHMA; BREATHING RATE; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 53649102551     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2008.102327     Document Type: Letter

References (5)

1. Cogo A, Fischer R, Schoene R. Respiratory diseases at altitude. High Alt Med Biol 2004;5:435-44.
2. Kaminsky DA, Irvin CG, Gurka DA, et al. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med 1995;152:1784-90.
3. Grootendorst DC, Dahlen SE, Van Den Bos JW, et al. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids. Clin Exp Allergy 2001;31:400-8.
4. O'Donnell WJ, Rosenberg M, Niven RW, et al. Acetazolamide and furosemide attenuate asthma induced by hyperventilation of cold, dry air. Am Rev Respir Dis 1992;146:1518-23.
5. Kalson N, Davies A, Stokes S, et al. Climbers with diabetes do well on Mount Kilimanjaro. Diabetes Med 2007;24:1496.